drugset
Drugs / Mitomycin C-induced peripheral blood mononuclear cells
last change May 2020 re-read 3 minutes ago

Mitomycin C-induced peripheral blood mononuclear cells

also known as MICs · modified immune cells

Cell therapy

Developed for
chronic kidney disease
Investigated by
German Federal Ministry of Economics and Technology · Heidelberg University · WiSP GmbH

Trials 1

today NCT02560220 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02560220 Aug 2015 → Apr 2017 chronic kidney disease Heidelberg University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Mitomycin C-induced peripheral blood mononuclear cells “Mitomycin C-induced peripheral blood mononuclear cells (MICs)” NCT02560220 ↗
Known as MICs ClinicalTrials.gov intervention name — accepted as the source's own label NCT02560220 ↗
Known as modified immune cells “Preclinical experiments have shown that donor blood cells, modified in vitro by an alkylating agent (modified immune cells [MICs]), induced long-term specific immunosuppression...” PMID 31990685 ↗ May 2020
Modality Cell therapy “MIC Cell Therapy” NCT02560220 ↗
Route Intravenous “MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor” NCT02560220 ↗